Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Prednisone for Myelofibrosis
NCT00352794Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2006
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement) at 6 months. Started Jul 2006; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00352794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352794.